Subtopic Deep Dive
Atropine Therapy for Myopia Control
Research Guide
What is Atropine Therapy for Myopia Control?
Atropine Therapy for Myopia Control uses low-dose atropine eye drops to slow axial elongation and refractive progression in children with myopia.
Randomized trials evaluate 0.01%, 0.1%, and 0.5% atropine doses for efficacy and side effects (Chia et al., 2011, 789 citations). Five-year follow-up confirms 0.01% atropine reduces progression without significant rebound (Chia et al., 2015, 589 citations). Over 20 trials since 1999 compare atropine to controls, optimizing dosing for minimal photophobia and near vision blur.
Why It Matters
Low-dose atropine slows myopia progression by 50-60% in Asian cohorts, reducing high myopia risk and associated maculopathy (Chia et al., 2011; Wildsoet et al., 2019). It influences guidelines like IMI reports for scalable pediatric interventions amid rising prevalence post-COVID confinement (Wang et al., 2021). Jonas et al. (2021) project 50% global myopia by 2050, positioning atropine as a first-line therapy to curb visual impairment costs exceeding $10B annually.
Key Research Challenges
Dose Optimization
Balancing efficacy against side effects like photophobia requires comparing 0.01-1% doses across trials (Chia et al., 2011; Shih et al., 1999). Lower doses reduce blur but may lose 20-30% effectiveness (Chia et al., 2015).
Rebound Myopia
Discontinuation after 2-5 years causes rebound progression exceeding controls in some cohorts (Chia et al., 2015). Long-term trials lack data beyond 5 years, complicating adherence (Wildsoet et al., 2019).
Population Variability
Efficacy varies by ethnicity and outdoor exposure, with weaker effects in non-Asian groups (Xiong et al., 2017; Jonas et al., 2021). Meta-analyses show 40% heterogeneity in axial elongation inhibition.
Essential Papers
Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)
Audrey Chia, Wei‐Han Chua, Yin‐Bun Cheung et al. · 2011 · Ophthalmology · 789 citations
Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2
Audrey Chia, Qingshu Lu, Donald Tan · 2015 · Ophthalmology · 589 citations
Time spent in outdoor activities in relation to myopia prevention and control: a meta‐analysis and systematic review
Shuyu Xiong, Padmaja Sankaridurg, Thomas Naduvilath et al. · 2017 · Acta Ophthalmologica · 575 citations
Abstract Outdoor time is considered to reduce the risk of developing myopia. The purpose is to evaluate the evidence for association between time outdoors and (1) risk of onset of myopia (incident/...
Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial
Carly Siu Yin Lam, Wing Chun Tang, Dennis Y. Tse et al. · 2019 · British Journal of Ophthalmology · 504 citations
Aim To determine if ‘Defocus Incorporated Multiple Segments’ (DIMS) spectacle lenses slow childhood myopia progression. Methods A 2-year double-masked randomised controlled trial was carried out in...
Progression of Myopia in School-Aged Children After COVID-19 Home Confinement
Jiaxing Wang, Ying Li, David C. Musch et al. · 2021 · JAMA Ophthalmology · 479 citations
This cross-sectional study compares the prevalence of myopia in school-aged children 5 years before the COVID-19 pandemic with the prevalence during home confinement due to the pandemic.
Scleral hypoxia is a target for myopia control
Hao Wu, Wei Chen, Fei Zhao et al. · 2018 · Proceedings of the National Academy of Sciences · 474 citations
Significance Myopia is the leading cause of visual impairment. Myopic eyes are characterized by scleral extracellular matrix (ECM) remodeling, but the initiators and signaling pathways underlying s...
IMI – Interventions for Controlling Myopia Onset and Progression Report
Christine F. Wildsoet, Audrey Chia, Pauline Cho et al. · 2019 · Investigative Ophthalmology & Visual Science · 421 citations
Myopia has been predicted to affect approximately 50% of the world's population based on trending myopia prevalence figures. Critical to minimizing the associated adverse visual consequences of com...
Reading Guide
Foundational Papers
Start with Chia et al. (2011, 789 citations) for dose comparisons; Shih et al. (1999, 278 citations) for early concentration effects.
Recent Advances
Chia et al. (2015, 589 citations) for 5-year data; Wildsoet et al. (2019, 421 citations) and Jonas et al. (2021, 391 citations) for IMI intervention syntheses.
Core Methods
Cycloplegic autorefraction, partial coherence interferometry for axial length, logMAR acuity for side effects; statistical models include mixed-effects for progression rates.
How PapersFlow Helps You Research Atropine Therapy for Myopia Control
Discover & Search
Research Agent uses searchPapers for 'atropine 0.01% myopia control RCTs' to retrieve Chia et al. (2011, 789 citations); citationGraph maps 500+ citing papers; findSimilarPapers links to Chia et al. (2015); exaSearch uncovers dose-response meta-analyses.
Analyze & Verify
Analysis Agent applies readPaperContent to extract progression rates from Chia et al. (2011); verifyResponse with CoVe cross-checks rebound claims against 10 trials; runPythonAnalysis computes meta-effect sizes via GRADE grading, verifying 0.01% slows elongation by 0.13mm/year (p<0.001).
Synthesize & Write
Synthesis Agent detects gaps in rebound data post-5 years; Writing Agent uses latexEditText for trial comparisons, latexSyncCitations for 20+ refs, latexCompile for publication-ready tables; exportMermaid visualizes dose-efficacy flowcharts.
Use Cases
"Run meta-analysis on atropine dose vs. axial length change from RCTs"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-regression on elongation data from Chia 2011/2015) → GRADE-verified effect size plot (0.01% best risk-benefit).
"Draft review section on atropine rebound effects with tables"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Chia 2015 et al.) → latexCompile → PDF with formatted progression tables.
"Find code for modeling atropine myopia progression"
Research Agent → paperExtractUrls (Wu 2018 scleral hypoxia) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on simulation scripts for dose-response curves.
Automated Workflows
Deep Research workflow scans 50+ atropine papers via searchPapers → citationGraph → structured report with GRADE tables on efficacy. DeepScan applies 7-step CoVe to verify rebound claims from Chia et al. (2015) against IMI reports. Theorizer generates hypotheses on atropine-scleral hypoxia links from Wu et al. (2018).
Frequently Asked Questions
What is Atropine Therapy for Myopia Control?
Low-dose (0.01-0.1%) atropine eye drops slow childhood myopia progression by inhibiting axial elongation, as shown in RCTs (Chia et al., 2011).
What are key methods in atropine trials?
Double-masked RCTs compare atropine doses to placebo, measuring cycloplegic refraction and axial length via ultrasound/autorefraction over 2-5 years (Chia et al., 2011; 2015).
What are landmark papers?
Chia et al. (2011, Ophthalmology, 789 citations) established 0.01% efficacy; Chia et al. (2015) confirmed 5-year safety (589 citations).
What open problems remain?
Long-term rebound after 5+ years, ethnic variability, and combination with orthokeratology need multi-center trials (Wildsoet et al., 2019; Jonas et al., 2021).
Research Ophthalmology and Visual Impairment Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Atropine Therapy for Myopia Control with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers